Is Elevance Health (ELV) Trading At A Discount After Strong Q2 And Higher Outlook?

Elevance Health (ELV) is back in focus after reporting strong Q2 2026 results, lifting its full year outlook and highlighting AI driven efficiency gains, along with new leadership for Carelon Behavioral Services.

Over the past year Elevance Health has seen a solid build in momentum, with a 1 year total shareholder return of 31.28% alongside a 12.66% year to date share price return. AI driven efficiency gains and the Carelon leadership change help frame recent moves around the current US$399.11 share price.

Spot opportunities alongside Elevance Health by reviewing the hand picked 46 high quality undervalued stocks that combine stronger fundamentals with more reasonable pricing.

Elevance Health now trades at a clear discount to its most followed fair value estimates despite solid results and a lifted outlook. Is that a sign of market caution that makes sense, or a gap worth examining through valuation?

Most Popular Narrative: 11.1% Undervalued

At a last close of $399.11, the most widely followed narrative anchors Elevance Health's fair value at about $449.10, implying a valuation gap built on specific revenue, margin, and discount rate assumptions.

Strategic investments in digital consumer engagement and Carelon's diversified health services (e.g., pharmacy, care management, behavioral health) are accelerating revenue growth and providing higher-margin, recurring income streams, which should drive both topline and earnings diversity as industry healthcare spending and complexity continue to rise.

Read the complete narrative. Read the complete narrative.

Want to understand why this Elevance Health valuation leans on measured revenue growth, higher margins, and a lower future earnings multiple than many healthcare peers? The full narrative spells out the earnings path and cash flow assumptions behind that 11.1% discount, and what would need to happen operationally for the fair value estimate to keep holding up.

Result: Fair Value of $449.10 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, investors still need to watch Medicaid utilization pressures and the risk that slower state rate adjustments or market exits could leave Elevance Health carrying underpaid medical costs.

Find out about the key risks to this Elevance Health narrative.

Next Steps

With sentiment around Elevance Health leaning positive, this is a good moment to move quickly and pore over the details yourself. To see why some investors are focusing on specific upsides, review the 4 key rewards.

Looking for more investment ideas beyond Elevance Health?

If Elevance Health has sharpened your focus, do not stop here. Broaden your watchlist with other opportunities that match your risk, income, and quality goals.

• Target potential value opportunities by scanning a 46 high quality undervalued stocks that may trade on stronger fundamentals than their current prices suggest.
• Strengthen your income stream by reviewing a 12 dividend fortresses that aim to combine higher yields with resilient payouts.
• Prioritise resilience by searching a 76 resilient stocks with low risk scores that screens for companies with steadier profiles and lower overall risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com